Browsing Over 32 Presentations

Sort By
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

Q&A (ID 11)

Lecture Time
16:10 - 16:20
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
The role of CDK along the mitotic process in normal and pathological condition (ID 3) Educational session

Q&A (ID 6)

Lecture Time
14:00 - 14:10
Session Name
The role of CDK along the mitotic process in normal and pathological condition (ID 3)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
13:20 - 14:30
Welcome and introduction (ID 1) Educational session

Welcome to the Symposium (ID 34)

Lecture Time
11:30 - 11:45
Speakers
  • Alberto Bardelli (Candiolo, IT)
  • Josep Tabernero (Barcelona, ES)
Session Name
Welcome and introduction (ID 1)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
11:30 - 11:45
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Ribociclib (ID 29)

Lecture Time
13:50 - 14:10
Speakers
  • Fabrice AndrĂ© (Villejuif, FR)
Session Name
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
The disappointing results of initial CDKI and their role in other disease (ID 7) Educational session

Roscovitine (ID 23)

Lecture Time
11:35 - 12:00
Speakers
  • Laurent Meijer (Roscoff, FR)
Session Name
The disappointing results of initial CDKI and their role in other disease (ID 7)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

RAS/RAF pathway (ID 18)

Lecture Time
09:20 - 09:40
Speakers
  • Federica Di Nicolantonio (Candiolo, IT)
Session Name
Interaction between CDKs, CDKI and other targets (ID 6)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50
Preclinical evidence of efficacy (ID 5) Educational session

Preclinical evidence of activity of ribociclib (ID 13)

Lecture Time
17:00 - 17:20
Speakers
  • Gustavo Baldassarre (Aviano, IT)
Session Name
Preclinical evidence of efficacy (ID 5)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
16:40 - 18:10
The concept of CDK inhibition according to the targeted CDK subtype (ID 4) Educational session

The role of CDK4, CDK2 and CDK1 in KRas driven lung tumors: The good, the bad and the ugly (ID 8)

Lecture Time
15:10 - 15:30
Speakers
  • Mariano Barbacid (Madrid, ES)
Session Name
The concept of CDK inhibition according to the targeted CDK subtype (ID 4)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
14:30 - 16:20
Keynote lecture (ID 2) Keynote lecture

The cell cycle regulation and biological basis of CDK inhibition (ID 1)

Lecture Time
11:45 - 12:05
Speakers
  • Marcos Malumbres (Madrid, ES)
Session Name
Keynote lecture (ID 2)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
23.03.2018
Time
11:45 - 12:30
CDK4 and CDK6 inhibitors in breast cancer (ID 8) Educational session

Are all CDK 4-6 created equal? (ID 31)

Lecture Time
14:30 - 14:50
Speakers
  • Giuseppe Curigliano (Milan, IT)
Session Name
CDK4 and CDK6 inhibitors in breast cancer (ID 8)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
13:30 - 15:00
The disappointing results of initial CDKI and their role in other disease (ID 7) Educational session

Q&A (ID 26)

Lecture Time
12:25 - 12:40
Session Name
The disappointing results of initial CDKI and their role in other disease (ID 7)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
11:10 - 12:40
Interaction between CDKs, CDKI and other targets (ID 6) Educational session

MEK (ID 20)

Lecture Time
10:00 - 10:20
Speakers
  • Olivier Michielin (Lausanne, CH)
Session Name
Interaction between CDKs, CDKI and other targets (ID 6)
Location
Auditorium, Vall d'Hebron, Barcelona, Spain
Date
24.03.2018
Time
09:00 - 10:50